This finding highlighted the significance of DAB2IP as a potential regulatory factor that could counteract the oncogenic actions of tRF‐34‐P4R8YP9LON4VHM, further elucidating the complex interplay between these molecular players in HCC. This evidence concerns the gene DAB2IP and hepatocellular carcinoma.